GAfPA Blog

The GAfPA Patient Advocacy Blog

Regulators Stand Up for Biosimilars

Development of biosimilars has expanded patients’ treatment options by offering innovative medicine at lower costs than traditional biologics. So why are some nations slow to adopt biosimilars?

Patients at the Heart of New Cholesterol Guidelines

The European Society of Cardiology has released new guidelines recommending that patients lower their LDL cholesterol to reduce their risk of cardiovascular disease. But the guidelines don’t just reinforce an important truth. They make it actionable for patients.

Can Health Research Survive Brexit?

The United Kingdom’s Brexit saga has captured the attention of the world.  But it’s also sparked concerns among British patients, researchers and health care advocates, who are asking: How will health research and innovation fare after the UK severs ties with the European Union? Research on cardiovascular disease provides an apt example.  According to the … Continued

Heart Disease Deaths Climb in the UK

For the first time in 50 years, heart disease-related deaths in the United Kingdom are mounting.  The likely cause? Health disparities and uncontrolled risk factors. The British Heart Foundation reports that 42,384 people under age 75 died from heart-related diseases in 2017. That’s up four percent from 2014.  Before that, heart disease-related death rates were … Continued

Sign up to receive updates from GAfPA